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Background: Patients with COPD are often characterized by disturbed metabolic health which is reflected
in altered body composition. Current studies in healthy subjects suggest that resveratrol improves
metabolic health by enhancing muscle mitochondrial function and adipose tissue morphology. The
primary objective was to investigate the effect of four weeks resveratrol supplementation on muscle
mitochondrial function in patients with COPD. Secondary objectives were to investigate the effect of
resveratrol on adipose tissue inflammatory and metabolic gene expression, systemic inflammation and
body composition in patients with COPD.
Methods: In a double-blind randomized placebo-controlled proof-of-concept study, 21 COPD patients
(FEV1: 53 ± 15% predicted; age: 67 ± 9 years and BMI: 24.5 ± 3.3 kg/m2) received resveratrol (150 mg/
day) or placebo for four weeks. Before and after intervention, blood samples, quadriceps muscle and
subcutaneous abdominal fat biopsies were obtained for metabolic and inflammatory profiling. Body
composition was assessed by dual energy X-ray absorptiometry.
Results: Muscle mitochondrial biogenesis regulators AMPK, SIRT1 and PGC-1a as well as mitochondrial
respiration, Oxphos complexes, oxidative enzyme activities and kynurenine aminotransferases were not
improved by resveratrol. Plasma high-sensitive C-reactive protein and kynurenine did not change after
resveratrol supplementation. Adipose tissue inflammatory markers were unaffected by resveratrol, while
markers of glycolysis and lipolysis were significantly increased compared to placebo supplementation.
Body weight decreased after resveratrol supplementation (resveratrol 0.95 ± 1.01 kg vs
placebo 0.16 ± 0.66 kg, p ¼ 0.049) due to a reduction in lean mass (resveratrol 1.79 ± 1.67 kg vs
0.37 ± 0.86 kg, p ¼ 0.026).
Conclusion: We do not confirm previously reported positive effects of resveratrol on skeletal muscle
mitochondrial function in patients with COPD, but show an unexpected decline in lean mass.
Clinical trial registry: Clinicaltrials.gov NCT02245932.
© 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Chronic obstructive pulmonary disease (COPD) is not only
characterized by loss of lung function but also by reduced skeletal
muscle mass and loss or redistribution of adipose tissue mass,
which adversely affects metabolic health [1]. Decreased muscleMaastricht, the Netherlands.
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for Clinical Nutrition and Metabometabolic health is well established in COPD [2,3]. Next to loss of
muscle mass, intrinsic abnormalities include a shift from oxidative
type I towards glycolytic type II muscle fibers and a reduced
oxidative capacity [4,5]. Moreover, mitochondrial function is
impaired: skeletal muscle mitochondria of patients with COPD rely
more on the metabolically less-efficient complex-II driven mito-
chondrial respiration [6] and exhibit an increased reactive oxygen
species production [7,8]. Muscle biopsies of patients with COPD
also showed decreased protein levels of phosphorylated adenosinelism. All rights reserved.
Abbreviations
AMPK adenosine monophosphate-activated protein
kinase
ATGL adipose triglyceride lipase
CGI58 comparative gene identification-58
COPD chronic obstructive pulmonary disease
CRP C-reactive protein
DHEAS dehydrposoandrosterone sulfate
DHR dihydroresveratrol
FEV1 forced expiratory volume in 1 s
HDL high-density lipoprotein
HSL home-sensitive lipase
KATs kynurenine aminotransferases
LDL low-density lipoprotein
PPAR peroxisome proliferator-activated receptor
PGC-1a PPAR gamma coactivator 1a
SIRT1 sirtuin 1
T2DM type 2 diabetes mellitus
TFAM mitochondrial transcription factor A
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proliferator-activated receptor (PPAR) gamma coactivator 1a (PGC-
1a) [5,9,10]. In addition to skeletal muscle impairments in COPD,
adipose tissue is lost [11] or redistributed towards an increase in
ectopic fat [12]. Pro-inflammatory gene expression in subcutaneous
adipose tissue of very severe COPD patients was significantly
upregulated compared to moderate-severe COPD, despite a lower
fat mass [13]. Systemic inflammation is also common in COPD [1].
Besides commonly employed markers of low-grade systemic
inflammation, recently, increased plasma levels of the inflamma-
tory marker kynurenine were reported in patients with COPD [14].
Interestingly, kynurenine can be cleared (by conversion into
kynurenic acid) in skeletal muscle by kynurenine aminotransfer-
ases (KATs)1e4, which are under the control of PGC-1a [15]. This
suggests that muscle impairments in COPD may further enhance
systemic inflammatory load as well.
The natural polyphenol resveratrol (3,5,40-trihydroxystilbene) is a
bioactive nutrient, that has recently received a lot of attention based
on promising multi-organ effects in experimental animal models
including anti-inflammatory, anti-oxidant and cardioprotective ef-
fects as well as boosting effects on mitochondrial function [16].
However, to date clinical validation of cardioprotective effects in
different target groups (i.e. obesity, type II diabetes, elderly) have
been rather disappointing [16]. Resveratrol may nevertheless be an
interesting pharmaconutrient for patients with COPD as it has been
shown to activate Sirtuin 1 (SIRT1), directly or indirectly via the
activation of AMPK, which subsequently activates PGC-1a, a master
regulator of mitochondrial metabolism and biogenesis [17]. In
addition, resveratrol supplementation in mice fed with a high-fat
diet showed an inhibition of adipogenesis and inflammation and
increased lipolysis in adipose tissue [18].
To our knowledge, no clinical study has been published inves-
tigating the systemic effects of resveratrol supplementation in pa-
tients with COPD. Therefore, the aim of this proof-of-concept study
was to assess the effects of four weeks resveratrol supplementation
on skeletal muscle mitochondrial function as primary outcome and
on molecular signatures in muscle and adipose tissue biopsies,
systemic inflammation and body composition as secondary
outcome.2. Methods
2.1. Study design and subjects
A randomized placebo-controlled double-blind clinical trial was
conducted in clinically stable COPD patients. Patients were
recruited via advertisements in local newspapers in the neighbor-
hood of Maastricht, The Netherlands, between 2016 and 2017.
Exclusion criteria were recent (<4 weeks) exacerbation that
required oral steroids and/or hospitalization, diabetes mellitus (all
types), active cardiovascular disease or a cardiovascular event (such
as myocardial infarction, cerebrovascular haemorrhage/infarction)
in the previous 6 months, recent major surgery, thyroid dysfunc-
tion, hepatic and renal disorders, current malignancy or central or
obstructive sleep apnea. Furthermore, subjects using resveratrol
containing dietary supplements or subjects with current alcohol
consumption >20 g/day were excluded. All patients gave their
written informed consent. The study was registered at clinicaltrials.
gov (NCT02245932) and was approved by the Medical Ethics
Committee from Maastricht University Medical Centreþ (MUMCþ
[NL49391.068.14/MEC 14-3-016]).
2.2. Supplementation protocol
Subjects received either resveratrol (150 mg/day trans-
resveratrol [99.9%]; resVida; provided by DSM Nutritional Prod-
ucts Ltd.) or placebo for four weeks (28 days). This dose is much
higher than the dose of resveratrol that can be ingested though the
diet [19]. The resveratrol dosage and duration of supplementation
was based on several previous studies in healthy obese, type II
diabetes mellitus patients and first degree relatives of patients with
type II diabetes mellitus in which an improvement in muscle
mitochondrial function was found [20e22]. Randomization was
carried out by an independent researcher and the randomization
scheme was controlled for current smoking and gender using the
minimization method [23,24]. Both subjects and researchers were
blinded for the treatments until the end of the study analysis. Pa-
tients were instructed to take the first supplement after the mea-
surements on the first test-day and the last supplement in the
evening before the last test-day. On the last test-day, patients
returned unused capsules in order to check for compliance. Patients
were instructed to maintain their usual dietary intake and physical
activity pattern and use of medication and (if applicable) other
supplements during the intervention period. Supplement and
medication intake was checked by self-report and physical activity
pattern was checked by measuring physical activity levels during
the 7 days before the test-days using a dual-axis GT1M acceler-
ometer (ActiGraph™, LLC, Fort Walton Beach, FL, USA), as was
previously described [5]. To check compliance, resveratrol metab-
olites (trans-resveratrol and dihydroresveratrol (DHR)) were
measured by mass spectrometry in plasma as was previously
described [22]. Furthermore, general safety parameters (creatinine,
urea, sodium, potassium, Ƴ-glutamyl transferase, alanine amino-
transferase, aspartate aminotransferase and alkaline phosphatase)
were analyzed.
2.3. Measurements
See the supplementary material for a detailed description of the
measurements and the analysis.
A muscle biopsy of the vastus lateralis muscle of the dominant
leg was taken under local anesthesia (2% lidocaine) during fasting
conditions according to the technique by Bergstr€om et al. [25]. A
portion of the muscle tissue was directly frozen in liquid nitrogen
and stored at80 C until analyzing protein expression byWestern
Table 1
Baseline characteristics.
Placebo
(n ¼ 10)
Resveratrol
(n ¼ 11)
p-value
Age, y 65.3 ± 9.1 67.8 ± 9.0 0.532
Males, n (%) 5 (50.0) 7 (63.6) 0.528
Smoking status
Current smokers, n (%) 2 (20.0) 3 (27.3) 0.696
Former smokers, n (%) 8 (80.0) 8 (72.7)
FEV1/FVC, % 51.1 ± 9.1 44.8 ± 12.6 0.205
FEV1, %pred 60 ± 13 48 ± 14 0.067
FVC, %pred 91 ± 15 84 ± 12 0.255
BMI, kg/m2 24.9 ± 3.0 24.1 ± 3.7 0.594
Lean mass, kg 45.1 ± 7.4 46.3 ± 8.4 0.729
Fat mass, kg 24.9 ± 7.9 21.7 ± 7.0 0.330
Metabolic syndrome, n (%) 2 (20.0) 3 (27.3) 0.696
Total physical activity,
counts/min
221 ± 102 195 ± 89 0.532
Total steps per day 5385 ± 2372 4299 ± 2111 0.281
Data were analyzed using independent sample t-test or X2-square test and data
are presented as mean ± standard deviation or n (%). BMI; body mass index;
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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ber. Another portion (~50 mg) was immediately placed in ice-cold
preservation medium (BIOPS) for determination of ex vivo muscle
mitochondrial respiration using an oxygraph (OROBOROS In-
struments, Innsbruck, Austria) as previously described [26]. Briefly,
5 mg saponinwas solved in 1mL BIOPS. Subsequently, 50 mL of this
saponin/BIOPS solution was added to 5 mL BIOPS, in which muscle
fibers were incubated for 30 min. After permeabilization, muscle
fibers were transferred to the respiration chamber of the oxygraph
to measure oxygen consumption. Two substrate inhibition pro-
tocols were used to measure oxidative phosphorylation. In the first
protocol, substrates were added to the respiration chamber in the
order: malate (M), octanoyl carnitine (O), ADP, glutamate (G),
succinate (S), cytochrome C and fluoro-carboyl cyanide phenyl-
hydrazone (FCCP). The same substrates in the absence of octanoyl
carnitine were used in the second protocol. One patient was
excluded from muscle biopsy analyses because no muscle biopsy
was available and one patient was excluded from Western blot
analysis because no tissue was left for analysis.
A para-umbilically subcutaneous adipose tissue biopsy was
obtained during fasting conditions through needle biopsy. This
biopsy was snap-frozen in liquid nitrogen and stored at 80 C
until analyzing gene expression by qPCR. One patient was excluded
from these analyses because no adipose tissue biopsy was available.
Plasma kynurenine, kynurenic acid and tryptophan were
measured by high-performance liquid chromatography as
described previously [27]. The kynurenine to tryptophan ratio was
calculated as a measure of the inflammatory status. The kynurenic
acid to kynurenine ratio was calculated as a measure of the con-
version of kynurenine in the skeletal muscle.
Body composition was assessed by Dual Energy X-ray Absorp-
tiometry (DXA, Hologic, Discovery A, QDR Series, Bedford, MA,
USA). Furthermore, cardiometabolic risk parameters including
glucose, insulin, low-density and high-density lipoprotein (LDL and
HDL) cholesterol, total cholesterol, triglycerides and high sensitive
C-reactive protein were measured in fasting blood samples (see
supplementary methods). Blood pressure was measured and
metabolic syndrome was determined according to the NCEP ATP
definition [28]. Lung function was assessed using spirometry (Spi-
roPerfect™, Welch Allyn, Delft, the Netherlands) at the first test-
day.
2.4. Statistical analyses
Sample size calculationwas based on previous observed 10e20%
improvements in mitochondrial respiration after resveratrol sup-
plementation [20e22,29]. In total, 20 subjects were required to
achieve 80% power, with an assumed treatment difference of
0.435 mmol/min/kg (15%) after 4 weeks resveratrol and an
assumed standard deviation of 0.3 mmol/min/kg [7].
Statistical analyses were performed blinded using Statistical
Package for the Social Sciences (SPSS version 22 for Windows, SPSS
Inc. Chicago, IL). Results are presented as mean ± standard devia-
tion (SD) when normally distributed and as median (interquartile
range) if not normally distributed, unless indicated otherwise. All
data was checked on influential outliers which were subsequently
excluded. Differences between groups at baseline were compared
using Student t-test for continuous variables, Х2-test for categorical
variables and Kruskal Wallis test for continuous variables with
skewed distributions. Data were analyzed using a two-way
repeated measures ANOVA with treatment (resveratrol and pla-
cebo) and test-day (pre and post) as within subject factors. In case
of significant interactions (treatment  time), within group differ-
ences were analyzed using a paired sampled t-test. A p-value <0.05
was considered statistically significant.3. Results
Twenty-three subjects were randomized of whom 21 completed
the study (Supplementary Fig. 1). Baseline characteristics of these
21 subjects are summarized in Table 1: both groups were compa-
rable in age, gender and smoking status and no significant differ-
ences were observed in lung function, body composition and
metabolic health determined by prevalence and components of the
metabolic syndrome (for individual components see
Supplementary Table 5). Furthermore, both groups were compa-
rable in physical activity level (Table 1), which they maintained
during the intervention period (data not shown).
3.1. Compliance
Supplements were well-tolerated, no adverse events and no
effects on safety parameters were reported (Supplement Table 4).
Compliance was confirmed by the number of supplements
returned (96.6% compliance) and by analysis of plasma levels of
resveratrol and DHR. At baseline, both resveratrol and DHR were
below detection. After the intervention period both metabolites
were present at the expected levels in the resveratrol group
(resveratrol 469.2 ± 218.0 ng/mL and DHR 915.5 ± 635.1 ng/mL),
while both compounds were undetectable in the placebo group.
3.2. Skeletal muscle mitochondrial metabolism
Muscle biopsies were obtained from 20 subjects (n ¼ 10
resveratrol, n ¼ 10 placebo). Ex vivo muscle mitochondrial respi-
ration revealed no significant effects of resveratrol compared to
placebo. ADP-stimulated (state 3) respiration on a lipid substrate
(malate þ octanoyl-carnitine, MO) and upon parallel electron input
to both complex I and II (MOG and MOGS) was not changed after
resveratrol supplementation (Fig. 1B, C). Similar datawere found on
state 3 mitochondrial respiration upon complex I- and II-linked
substrates in the absence of a lipid-derived substrate (MG and
MGS) (Fig. 1D, E) and on maximal FCCP-induced uncoupled respi-
ration (Fig. 1F). Citrate synthase and hydroxyl-acyl CoA dehydro-
genase enzyme activities were also not affected by resveratrol
compared to placebo (Fig. 1G, H). Moreover, mitochondrial DNA
copy number, an index of mitochondrial mass, did not change
significantly by resveratrol compared to placebo (D38.8 ± 573.6
Fig. 1. Muscle mitochondrial respiration and Oxphos complex protein levels before (white bars) and after (black bars) resveratrol (n ¼ 10) and placebo supplementation
(n ¼ 10). Oxidative capacity by means of ex vivo respirometry on skeletal muscle tissue: (AeC) ADP stimulated respiration (state 3) upon a lipid-like substrate and upon parallel
electron input into complex I and II; (DeF) ADP stimulated respiration (state 3) in the absence of a lipid-derived substrate and upon parallel electron input into complex I and II; (G)
Citrate synthase activity; (H) Hydroxy acyl-CoA dehydrogenase (HAD) activity; (IeL) Protein content of the individual complexes of the electron transport chain analyzed by
Western Blot (resveratrol n ¼ 9 and placebo n ¼ 10). Values are arbitrary units relative to baseline measurement of the placebo group, unless indicated otherwise. Data are
presented as individual data points and mean ± SEM. AU, Arbitrary Units; FCCP; carbonyl cyanide p-trifluoromethoxyphenylhydrazone; G, glutamate; M, malate; O, octanoyl-
carnitine; Oxphos, oxidative phosphorylation; S, succinate. Data were analyzed using a two-way repeated measures ANOVA with treatment and test-day as within subject fac-
tors. None of the time  treatment interactions were statistically significant.
R.JHCG. Beijers et al. / Clinical Nutrition 39 (2020) 2989e29972992vs 30.5 ± 377.6 AU after resveratrol vs placebo, p ¼ 0.754). Similar
results were obtained if respiration rates were corrected for mito-
chondrial DNA copy number or citrate synthase (data not shown).
Protein content of the individual Oxphos complexes (Fig. 1IeL),A
D
B
E
Fig. 2. Muscle protein levels of mitochondrial biogenesis regulators before (white bars)
AMPK; (B) phosphorylated AMPK; (C) Ratio of phosphorylated AMPK to total AMPK protein
arbitrary units relative to baseline (pre) measurement of the placebo group. AU, Arbitrary Un
using a two-way repeated measures ANOVA with treatment and test-day as within subjectmitochondrial biogenesis regulators AMPK, SIRT1 and PGC-1a
(Fig. 2) as well as gene expression of these markers (Supplementary
Fig. 2) revealed no significant differences after resveratrol supple-
mentation compared to placebo.C
and after (black bars) resveratrol (n ¼ 9) and placebo supplementation (n ¼ 10). (A)
expression; (D) Sirtuin 1 protein expression; (E) PGC-1a protein expression. Values are
its. Data are presented as individual data points and mean ± SEM. Data were analyzed
factors. None of the time  treatment interactions were statistically significant.
Table 2
Plasma high-sensitive C-reactive protein, kynurenine, kynurenic acid and tryptophan levels.
Placebo (n ¼ 10) Resveratrol (n ¼ 11) p-value
Before After Before After
Hs-CRP, mg/L 2.3 (1.4, 3.2) 2.4 (1.9, 6.0) 2.9 (1.8, 7.8) 2.1 (1.6, 4.7) 0.114
KYN, ng/mL 635 (498, 726) 636 (544, 779) 597 (417, 679) 535 (406, 612) 0.132
Trp, ng/mL 11,384 (10,493, 12,342) 12,406 (11,268, 13,486)a 12,578 (9529, 14,781) 11,362 (8879, 13,445) 0.006
KYNA, ng/mL 25.2 (12.1, 47.5) 16.3 (12.0, 24.1) 6.4 (3.4, 30.1) 13.8 (2.9, 34.2) 0.132
KYN/Trp 0.06 (0.04, 0.06) 0.05 (0.04, 0.06) 0.05 (0.04, 0.06) 0.04 (0.04, 0.05) 0.468
KYN/KYNA 19.7 (14.7, 73.2) 36.0 (30.9, 50.4) 98.6 (13.9, 205.9) 29.4 (18.6, 176.4) 0.099
Data were analyzed using Kruskal Wallis test for continuous variables with skewed distributions and results are presented as median (interquartile range).
Hs-CRP, High-sensitive C-reactive protein, KYN, kynurenine; KYNA, kynurenic acid; Trp, tryptophan.
p-values < 0.05 are indicated in bold.
a Significantly different from baseline. p-value shows time  treatment comparison.
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Baseline plasma levels of high-sensitive CRP, tryptophan,
kynurenine and kynurenic acid were not different between both
intervention groups and did not correlate with diseases severity
(data not shown). Plasma levels of high-sensitive CRP were not
affected by resveratrol supplementation. Plasma levels of trypto-
phan significantly increased after placebo supplementation, which
was significantly different from resveratrol supplementation
(Table 2). Plasma kynurenine and kynurenic acid as well as the
ratios between kynurenine, tryptophan and kynurenic acid did not
significantly change after resveratrol supplementation. Protein and
gene expression levels were not significantly affected by resveratrol
supplementation (Fig. 3).3.4. Adipose tissue inflammatory and metabolic gene expression
Adipose tissue biopsies were obtained from 20 subjects (n ¼ 10
resveratrol, n ¼ 10 placebo). Gene expression levels of markers of
inflammation and macrophages were not significantly different
after resveratrol supplementation compared to placebo (Fig. 4).
Changes in markers of glycolysis and lipolysis were significantly
different between the resveratrol and placebo group, in whichFig. 3. Protein and gene expression levels of kynurenine aminotransferases (KAT) 1e4
plementation (n ¼ 10). Protein expression of (A) KAT1; (B) KAT2; (C) KAT3; (D) KAT4; by W
KAT2; (C) KAT3; (D) KAT4 by qPCR. Values are arbitrary units relative to baseline (pre) measu
points and mean ± SEM. Data were analyzed using a two-way repeated measures ANOVA w
within group differences were analyzed using a paired sampled t-test. Only p-values for stmarkers increased after resveratrol supplementation while they
decreased after placebo supplementation (Fig. 5). Gene expression
levels of adipokines, mitochondrial markers and markers of hyp-
oxia were not significantly affected by resveratrol supplementation
(Supplementary Fig. 3).
3.5. Body composition
Body weight significantly decreased after resveratrol supple-
mentation compared to placebo supplementation (0.95 ± 1.01 kg
vs 0.16 ± 0.66 kg, p ¼ 0.049) due to a significant decrease in lean
mass (Fig. 6). Changes in lean mass significantly correlated with
changes in body weight (r ¼ 0.441, p ¼ 0.046). Body fat mass was
not significantly altered after resveratrol supplementation
compared to placebo. The changes in lean mass were not related to
changes in protein and gene expression levels of anabolic and
catabolic markers in skeletal muscle (Supplementary Fig. 4).
4. Discussion
To our knowledge, this is the first clinical study investigating the
effects of resveratrol supplementation in patients with COPD. We
report no changes in skeletal muscle mitochondrial respiration, before (white bars) and after (black bars) resveratrol (n ¼ 10) and placebo sup-
estern Blot (resveratrol n ¼ 9 and placebo n ¼ 10) and gene expression of (E) KAT1; (B)
rement of the placebo group. AU, Arbitrary Units. Data are presented as individual data
ith treatment and test-day as within subject factors. In case of significant interactions,
atistically significant time  treatment interactions are shown.
Fig. 4. Adipose tissue gene expression levels of markers of inflammation and macrophages, before (white bars) and after (black bars) resveratrol (n ¼ 10) and placebo
supplementation (n ¼ 10). Gene expression of (A) Interleukin-8 (IL-8); (B) Monocyte chemotactic protein-1 (MCP-1); (C) CD68; (D) CD163; (E) CD206; (F) CD11b. AU, Arbitrary
Units. Data are presented as individual data points and mean ± SEM. Data were analyzed using a two-way repeated measures ANOVAwith treatment and test-day as within subject
factors. None of the time  treatment interactions were statistically significant.
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in muscle AMPK, SIRT1 or PGC-1a were found. Systemic and adi-
pose tissue inflammatorymarkers were unaffected after resveratrol
supplementation but a differential response in adipose tissue
glycolytic and lipolytic marker expression was observed between
the groups, in which expression seemed to decrease after placebo
supplementation while it maintained or even increased after
resveratrol supplementation. A significant between group differ-
ence in body weight was observed, due to a reduction in lean mass
after resveratrol supplementation.
Resveratrol is a SIRT1 activator, directly or indirectly via AMPK,
that subsequently activates PGC-1a [17]. In the current study, SIRT1
and phosphorylated AMPK tended to increase after resveratrol
supplementation, however this was not significantly different from
theplacebo group and this tendencywas also not found for the otherA
D
B
E
Fig. 5. Adipose tissue gene expression levels of markers of glycolysis and lipolysis, be
mentation (n ¼ 10). Gene expression of (A) Hexokinase II; (B) Comparative gene identificati
(E) Perilipin. AU, Arbitrary Units. Data are presented as individual data points and mean ± SE
test-day as within subject factors. In case of significant interactions, within group difference
time  treatment interactions are shown.mitochondrial biogenesis markers downstream of SIRT1. Further-
more, muscle mitochondrial respiration did not significantly in-
crease after resveratrol supplementation compared to placebo.
These findings are not in agreement with previous studies in over-
weight and obese subjects, T2DM patients and relatives of T2DM
patients [20e22,29], in which improved muscle mitochondrial
respiration on the electron input of both complexes I and II after
resveratrol supplementation was reported [20,22,29]. These im-
provements were also observed in the absence of increased AMPK
and PGC-1a levels [21]. Three of these studies used a crossover
design, but the samedose of resveratrol for a comparable duration of
30 days in respectively n ¼ 13, n ¼ 17 and n ¼ 11 subjects [20e22].
Plasma levels of tryptophan significantly increased after placebo
supplementation, which was significantly different from resvera-
trol supplementation. This differential response corresponds toC
fore (white bars) and after (black bars) resveratrol (n ¼ 10) and placebo supple-
on-58 (CGI-58); (C) Adipose triglyceride lipase (ATGL); (D) Home-sensitive lipase (HSL).
M. Data were analyzed using a two-way repeated measures ANOVAwith treatment and
s were analyzed using a paired sampled t-test. Only p-values for statistically significant
Fig. 6. Changes in lean mass after placebo (n ¼ 10) and resveratrol (n ¼ 11) sup-
plementation. Data were analyzed using a two-way repeated measures ANOVA with
treatment and test-day as within subject factors. Within group differences were
analyzed using a paired sampled t-test.
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resveratrol and showed a significant decrease in plasma tryptophan
levels [30]. However, the latter study also found slightly elevated
kynurenine levels after resveratrol supplementation, which resul-
ted in a significantly increased kynurenine to tryptophan ratio.
These features of the kynurenine pathway were not affected in the
current study. Since we also did not find an effect of resveratrol on
the expression of PGC-1a in skeletal muscle and subsequently not
on the KATs, the lack of this effect may not be completely surpris-
ing. Change in tryptophan might have an effect on mood as tryp-
tophan is a precursor of serotonin synthesis [31,32]. Assessing
mood however was outside the scope of this study, but might be
relevant in future clinical trials.
A striking observation was a significant within and between
group decrease in body weight and specifically in lean body mass
after resveratrol. A recent comprehensive metabolomics analysis
in blood, urine, fat and skeletal muscle showed that the most
pronounced effect of four months resveratrol in middle aged men
with metabolic syndrome was a change in steroid hormones
across all four matrices, in which sulfated androgen precursors
were reduced in blood, adipose tissue, and muscle tissue and
increased in urine [33]. More specifically, in skeletal muscle the
sulfated steroid metabolites dehydroisoandrosterone sulfate
(DHEAS), epiandrosterone sulfate, androsterone sulfate and 4-
adrosten3b, and 17b-diol disulfate 1 were significantly
decreased. This may be relevant for (sarcopenic) patients with
COPD as previous research showed that serum DHEAS levels
were significantly lower in patients with low compared to
normal mid-thigh cross-sectional area [34]. Ratios between the
catabolic cytokine interleukin-1 and the catabolic hormone
cortisol to the anabolic hormone DHEAS were also significantly
lower in COPD patients with low mid-thigh cross-sectional area
compared to controls. An imbalance between anabolic and
catabolic systemic triggers may affect muscle protein turnover
and drive muscle wasting in COPD. It could be speculated that
resveratrol stimulates catabolic signaling in muscle. However, in
the current study markers of anabolic and catabolic processes
(Supplementary Fig. 4) were not changed in muscle biopsies after
resveratrol supplementation. These findings are in contrast to
observations from experimental models. In C2C12 and L6 myo-
tubes or mice treated with catabolic inflammatory or hormonal
triggers (tumor necrosis factor (TNF)-a or dexamethasone),
expression of the atrogenes atrogin-1 and MuRF1 was increased
[35e37], but prevented when resveratrol was simultaneously
administered. A recent meta-analysis confirmed a decrease inbody weight albeit after longer-term intervention [38]. The fact
that the currently reported weight decrease was due to a
decrease in lean mass was unexpected and seems to contrast
with limited available data in healthy (obese) subjects [39,40]. In
view of the enormous popularity of resveratrol use in the US
(annual growth of 5.8% since 2013 [41]), our data call for further
investigation in COPD.
Subcutaneous adipose tissue biopsies were primarily obtained
to analyze inflammatory markers, which were unaffected by
resveratrol supplementation in line with an unaltered systemic
inflammatory profile. Secondary and similar to the muscle biopsies,
we analyzed metabolic markers of oxidative metabolism in these
adipose tissue biopsies, which showed significant differences in
gene expression levels of somemarkers of lipolysis and glycolysis. A
previous study investigated the effect of resveratrol on lipolysis in
human and murine adipocytes and adipose tissue of mice and
specifically assessed the involvement of adipose triglyceride lipase
(ATGL) and home-sensitive lipase (HSL) [42]. This study reported
that resveratrol increased lipolysis mainly through enhancing ATGL
expression. We did not find an effect of resveratrol on ATGL
expression but we did find significant between group differences in
expression of lipolysis markers comparative gene identification-58
(CGI58), HSL and perilipin. The current study furthermore showed
increased hexokinase II gene expression after resveratrol supple-
mentation. More research is needed regarding the effect of
resveratrol on adipose tissue oxidative metabolism in COPD.
Several limitations of the current study need to be considered.
One could argue that the absence of a healthy control group to
confirm a decreasedmitochondrial function in COPD, is a limitation
of the current study. However, the aim of this RCT was based on
consistent previous research showing impaired muscle mitochon-
drial function in patients with COPD and comparable airflow
obstruction [5,9,43]. Despite randomization, lung function tended
to be lower in the resveratrol group. However, this was not statis-
tically significant and airflow obstruction did not correlate with any
changes in mitochondrial function and body composition (data not
shown). Moreover, physical activity level was comparable between
the groups. Another limitation is that dietary intake was not eval-
uated in this study, which next to elevated energy requirements
could have contributed to the observed bodyweight changes in this
study. However, one might expect that a resveratrol-induced effect
on energy balance might primarily affect fat tissue instead of the
observed decreased lean mass. Bioavailability of resveratrol is low
[44], but in the current study, the dose and duration were based on
previous studies showing beneficial effects of resveratrol on mito-
chondrial function [20e22]. Since these studies did find significant
improvements in muscle mitochondrial function after 4 weeks
resveratrol supplementation of 150 mg/day, it is believed that the
4-week intervention period in the current studywould be sufficient
to find relevant changes in mitochondrial function. Moreover, the
total plasma resveratrol levels were even higher in the current
study compared to these previous studies (183e412 ng/mL).
In conclusion, the present study in patients with COPD showed
no beneficial effect of four weeks resveratrol supplementation on
skeletal muscle mitochondrial function, systemic and adipose tis-
sue inflammation, but seemed to affect adipose tissue oxidative
metabolism. Remarkably and unexpected, four weeks of resveratrol
decreased body weight due to decreased lean mass, which calls for
further investigation, particularly if resveratrol is being considered
as a candidate intervention targeting lung injury in COPD.
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